Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense oligonucleotides targeting p53 cryptic exon
- Development stage
- Preclinical
- Lead developer
- Indiana University School of Medicine
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Antisense oligonucleotides targeting the p53 cryptic exon are splice-switching oligonucleotides designed to modulate the expression of p53 isoforms. Developed by researchers at the Indiana University School of Medicine, these oligonucleotides target a stress-responsive cryptic exon embedded in the first intronic region of the p53 gene. Under stress conditions, a short transcript consisting of the first canonical exon and this cryptic exon is expressed, which normally limits canonical p53 expression. By targeting this cryptic exon or its transcription termination site, these antisense oligonucleotides can differentially control the expression of the short transcript and canonical p53, thereby enhancing canonical p53 expression to protect against ischemia-reperfusion injury and facilitate tissue recovery in acute kidney injury.
- Other names
- antisense oligonucleotides targeting p53 short isoformsplice-switching antisense oligonucleotides targeting p53 cryptic exon
Beyond the preview
Go deeper on antisense oligonucleotides targeting p53 cryptic exon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense oligonucleotides targeting p53 cryptic exon.